

# Kris V Kowdley

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6488477/publications.pdf>

Version: 2024-02-01

136  
papers

18,462  
citations

28242

55  
h-index

15249

126  
g-index

143  
all docs

143  
docs citations

143  
times ranked

15827  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis. <i>New England Journal of Medicine</i> , 2010, 362, 1675-1685.	13.9	2,718
2	Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. <i>Lancet, The</i> , 2015, 385, 956-965.	6.3	1,840
3	Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis. <i>New England Journal of Medicine</i> , 2014, 370, 1879-1888.	13.9	1,080
4	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019, 394, 2184-2196.	6.3	818
5	A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. <i>New England Journal of Medicine</i> , 2016, 375, 631-643.	13.9	817
6	High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. <i>Hepatology</i> , 2009, 50, 808-814.	3.6	603
7	A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. <i>Hepatology</i> , 2018, 67, 1754-1767.	3.6	528
8	Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid. <i>Gastroenterology</i> , 2015, 148, 751-761.e8.	0.6	470
9	Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2012, 55, 77-85.	3.6	412
10	ACG Clinical Guideline: Primary Sclerosing Cholangitis. <i>American Journal of Gastroenterology</i> , 2015, 110, 646-659.	0.2	400
11	Levels of Alkaline Phosphatase and Bilirubin Are Surrogate End Points of Outcomes of Patients With Primary Biliary Cirrhosis: An International Follow-up Study. <i>Gastroenterology</i> , 2014, 147, 1338-1349.e5.	0.6	365
12	Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin. <i>Hepatology</i> , 2012, 56, 422-433.	3.6	342
13	Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. <i>Gastroenterology</i> , 2015, 149, 1804-1812.e4.	0.6	330
14	Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 156-163.e2.	2.4	322
15	Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naïve patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. <i>Lancet, The</i> , 2013, 381, 2100-2107.	6.3	265
16	Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1. <i>New England Journal of Medicine</i> , 2014, 370, 222-232.	13.9	262
17	Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2011, 53, 448-457.	3.6	261
18	Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. <i>Clinics in Liver Disease</i> , 2018, 22, 23-37.	1.0	233

#	ARTICLE	IF	CITATIONS
19	Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. <i>Nature Genetics</i> , 2017, 49, 269-273.	9.4	230
20	Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease. <i>JAMA Network Open</i> , 2019, 2, e1912565.	2.8	230
21	Genecriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study. <i>Hepatology</i> , 2020, 72, 892-905.	3.6	227
22	A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. <i>Hepatology</i> , 2018, 67, 1890-1902.	3.6	204
23	Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir. <i>Gastroenterology</i> , 2016, 151, 501-512.e1.	0.6	192
24	Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease. <i>Hepatology</i> , 2018, 67, 134-144.	3.6	192
25	Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 417-426.	2.4	191
26	The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis. <i>Hepatology</i> , 2019, 70, 788-801.	3.6	180
27	Hepatitis B Virus-Specific and Global T-Cell Dysfunction in Chronic Hepatitis B. <i>Gastroenterology</i> , 2016, 150, 684-695.e5.	0.6	178
28	Saroglitazar, a PPAR $\alpha/\delta$ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial. <i>Hepatology</i> , 2021, 74, 1809-1824.	3.6	163
29	Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib. <i>Journal of Hepatology</i> , 2019, 70, 133-141.	1.8	149
30	Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. <i>Journal of Hepatology</i> , 2019, 71, 357-365.	1.8	148
31	Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. <i>Contemporary Clinical Trials</i> , 2009, 30, 88-96.	0.8	140
32	Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. <i>Gut</i> , 2016, 65, 321-329.	6.1	139
33	ACG Clinical Guideline: Hereditary Hemochromatosis. <i>American Journal of Gastroenterology</i> , 2019, 114, 1202-1218.	0.2	136
34	Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION1, 2, and 3 clinical trials. <i>Hepatology</i> , 2015, 61, 1798-1808.	3.6	127
35	A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. <i>Journal of Hepatology</i> , 2014, 61, 1238-1246.	1.8	126
36	Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine. <i>Journal of Hepatology</i> , 2015, 63, 364-369.	1.8	115

#	ARTICLE	IF	CITATIONS
37	Iron alters macrophage polarization status and leads to steatohepatitis and fibrogenesis. <i>Journal of Leukocyte Biology</i> , 2019, 105, 1015-1026.	1.5	112
38	A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis. <i>Journal of Hepatology</i> , 2020, 73, 94-101.	1.8	111
39	Iron overload results in hepatic oxidative stress, immune cell activation, and hepatocellular ballooning injury, leading to nonalcoholic steatohepatitis in genetically obese mice. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 310, G117-G127.	1.6	109
40	Diagnosis and Management of Primary Biliary Cholangitis. <i>American Journal of Gastroenterology</i> , 2019, 114, 48-63.	0.2	100
41	The Metabolic Syndrome and Its Influence on Nonalcoholic Steatohepatitis. <i>Clinics in Liver Disease</i> , 2016, 20, 225-243.	1.0	85
42	Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials. <i>Hepatology</i> , 2015, 62, 25-30.	3.6	82
43	Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir. <i>Journal of Hepatology</i> , 2017, 66, 703-710.	1.8	81
44	Multicenter Validation of Association Between Decline in MRIâ€PDF and Histologic Response in NASH. <i>Hepatology</i> , 2020, 72, 1219-1229.	3.6	79
45	A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. <i>Journal of Hepatology</i> , 2021, 74, 1344-1354.	1.8	77
46	Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase. <i>American Journal of Gastroenterology</i> , 2020, 115, 1066-1074.	0.2	74
47	Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2019, 156, 88-95.e5.	0.6	73
48	A research agenda for curing chronic hepatitis B virus infection. <i>Hepatology</i> , 2018, 67, 1127-1131.	3.6	70
49	Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older. <i>Hepatology</i> , 2016, 63, 1112-1119.	3.6	67
50	Current and potential treatments for primary biliary cholangitis. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 306-315.	3.7	66
51	Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase Levels. <i>American Journal of Gastroenterology</i> , 2019, 114, 1626-1635.	0.2	65
52	Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome. <i>American Journal of Gastroenterology</i> , 2018, 113, 254-264.	0.2	64
53	Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a realâ€world cohort study. <i>Hepatology</i> , 2016, 64, 1893-1899.	3.6	61
54	Safety and efficacy of ledipasvirâ€sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data. <i>Hepatology</i> , 2016, 63, 437-444.	3.6	55

#	ARTICLE	IF	CITATIONS
55	Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history. <i>Hepatology</i> , 2018, 67, 1920-1930.	3.6	55
56	Management of chronic hepatitis B infection. <i>BMJ, The</i> , 2015, 351, h4263-h4263.	3.0	54
57	Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2076-2084.e2.	2.4	54
58	Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection. <i>Hepatology</i> , 2017, 65, 1094-1103.	3.6	53
59	Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial. <i>Gastroenterology</i> , 2016, 151, 902-909.	0.6	52
60	No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients. <i>Journal of Hepatology</i> , 2018, 69, 1221-1230.	1.8	50
61	EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study. <i>Journal of Hepatology</i> , 2022, 76, 506-517.	1.8	49
62	Relationship between three commonly used noninvasive fibrosis biomarkers and improvement in fibrosis stage in patients with nonalcoholic steatohepatitis. <i>Liver International</i> , 2019, 39, 924-932.	1.9	47
63	Nutritional Approaches to Achieve Weight Loss in Nonalcoholic Fatty Liver Disease. <i>Advances in Nutrition</i> , 2017, 8, 253-265.	2.9	38
64	Iron Deficiency in Patients With Nonalcoholic Fatty Liver Disease Is Associated With Obesity, Female Gender, and Low Serum Hcpidin. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1170-1178.	2.4	34
65	New developments in the treatment of primary biliary cholangitis &ndash; role of obeticholic acid. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 1053-1060.	0.9	34
66	Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021, 74, 274-282.	1.8	34
67	Data supporting updating estimates of the prevalence of chronic hepatitis B and C in the United States. <i>Hepatology</i> , 2015, 62, 1339-1341.	3.6	33
68	Iron overload disorders. <i>Hepatology Communications</i> , 2022, 6, 1842-1854.	2.0	33
69	Obeticholic acid in primary biliary cholangitis. <i>Current Opinion in Gastroenterology</i> , 2019, 35, 191-196.	1.0	30
70	Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1688-1697.e14.	2.4	30
71	Obeticholic acid for the treatment of nonalcoholic steatohepatitis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 311-321.	1.4	30
72	Hepcidin Signaling in Health and Disease: Ironing Out the Details. <i>Hepatology Communications</i> , 2021, 5, 723-735.	2.0	29

#	ARTICLE	IF	CITATIONS
73	Differences In Hepatic Expression of Iron, Inflammation and Stress-Related Genes in Patients with Nonalcoholic Steatohepatitis. <i>Annals of Hepatology</i> , 2017, 16, 77-85.	0.6	28
74	Hepatic R2* is more strongly associated with proton density fat fraction than histologic liver iron scores in patients with nonalcoholic fatty liver disease. <i>Journal of Magnetic Resonance Imaging</i> , 2019, 49, 1456-1466.	1.9	28
75	Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis. <i>Gut</i> , 2020, 69, 1502-1509.	6.1	28
76	Patient-Reported Outcomes Following Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Velpatasvir, With or Without Voxilaprevir. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 567-574.e6.	2.4	25
77	MicroRNAs in Liver Disease: Bench to Bedside. <i>Journal of Clinical and Experimental Hepatology</i> , 2013, 3, 231-242.	0.4	23
78	Development and validation of a primary sclerosing cholangitis-specific patient-reported outcomes instrument: The PSC PRO. <i>Hepatology</i> , 2018, 68, 155-165.	3.6	22
79	Application of Artificial Intelligence for Diagnosis and Risk Stratification in NAFLD and NASH: The State of the Art. <i>Hepatology</i> , 2021, 74, 2233-2240.	3.6	22
80	Association between metabolic syndrome and liver histology among NAFLD patients without diabetes. <i>BMJ Open Gastroenterology</i> , 2016, 3, e000114.	1.1	21
81	On-treatment <scp>HCV RNA</scp> as a predictor of sustained virological response in <scp>HCV</scp> genotype 3-infected patients treated with daclatasvir and sofosbuvir. <i>Liver International</i> , 2016, 36, 1611-1618.	1.9	20
82	Predicting outcome in primary biliary cirrhosis. <i>Annals of Hepatology</i> , 2014, 13, 316-26.	0.6	19
83	Mitochondrial DNA from hepatocytes as a ligand for TLR9: Drivers of nonalcoholic steatohepatitis?. <i>World Journal of Gastroenterology</i> , 2016, 22, 6965.	1.4	18
84	Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 684-692.e6.	2.4	17
85	Nonalcoholic Steatohepatitis Drug Development Pipeline: An Update. <i>Seminars in Liver Disease</i> , 2022, 42, 379-400.	1.8	17
86	Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis. <i>Hepatology Communications</i> , 2021, 5, 1201-1211.	2.0	16
87	Chronic Hepatitis C in Elderly Patients: Current Evidence with Direct-Acting Antivirals. <i>Drugs and Aging</i> , 2018, 35, 117-122.	1.3	15
88	The Role of Biliary Carcinoembryonic Antigen-Related Cellular Adhesion Molecule 6 (CEACAM6) as a Biomarker in Cholangiocarcinoma. <i>PLoS ONE</i> , 2016, 11, e0150195.	1.1	15
89	Isolation and characterization of iron chelators from turmeric ( <i>Curcuma longa</i> ): selective metal binding by curcuminoids. <i>BioMetals</i> , 2017, 30, 699-708.	1.8	14
90	Serum ferritin as a biomarker for NAFLD: ready for prime time?. <i>Hepatology International</i> , 2019, 13, 110-112.	1.9	14

#	ARTICLE	IF	CITATIONS
91	The Effects of Alcohol on Other Chronic Liver Diseases. <i>Clinics in Liver Disease</i> , 2016, 20, 581-594.	1.0	13
92	Curcumin and Turmeric Modulate the Tumor-Promoting Effects of Iron In Vitro. <i>Nutrition and Cancer</i> , 2017, 69, 481-489.	0.9	13
93	Haptoglobin 2 Allele is Associated With Histologic Response to Vitamin E in Subjects With Nonalcoholic Steatohepatitis. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, 750-758.	1.1	13
94	Current perspectives into the evaluation and management of hepatitis B: a review. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 361-369.	0.7	12
95	Relationship of ELF and PIIINP With Liver Histology and Response to Vitamin E or Pioglitazone in the PIVENS Trial. <i>Hepatology Communications</i> , 2021, 5, 786-797.	2.0	12
96	An Update on the Treatment and Follow-up of Patients with Primary Biliary Cholangitis. <i>Clinics in Liver Disease</i> , 2017, 21, 709-723.	1.0	10
97	Emerging drugs for the treatment of non-alcoholic steatohepatitis: a focused review of farnesoid X receptor agonists. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 251-260.	1.0	10
98	Characterization of patients with both alcoholic and nonalcoholic fatty liver disease in a large United States cohort. <i>World Journal of Hepatology</i> , 2019, 11, 710-718.	0.8	10
99	IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH. <i>Hepatology</i> , 2023, 77, 20-32.	3.6	10
100	Analysis of Subgroup Differences in the ION-3 Trial of Ledipasvir-Sofosbuvir in Chronic Hepatitis C Infection. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv056.	0.4	9
101	The Glasgow-Blatchford Bleeding Score identified patients with upper GI bleeding who could be managed as outpatients. <i>Annals of Internal Medicine</i> , 2009, 150, JC5.	2.0	8
102	Acidophil bodies in nonalcoholic steatohepatitis. <i>Human Pathology</i> , 2016, 52, 28-37.	1.1	8
103	Glyceronephosphate O-acyltransferase as a hemochromatosis modifier gene: Another iron in the fire?. <i>Hepatology</i> , 2015, 62, 337-339.	3.6	7
104	Role of ledipasvir/sofosbuvir combination for genotype 1 hepatitis C virus infection. <i>Hepatic Medicine: Evidence and Research</i> , 2016, Volume 8, 75-80.	0.9	7
105	A Proton Pump Inhibitor a Day Keeps the Iron Away. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 153-155.	2.4	7
106	Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease. <i>Kidney International Reports</i> , 2019, 4, 245-256.	0.4	7
107	Mechanisms and Treatments of Pruritus in Primary Biliary Cholangitis. <i>Seminars in Liver Disease</i> , 2019, 39, 209-220.	1.8	7
108	Investigational drugs in early phase development for primary biliary cholangitis. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 131-141.	1.9	7

#	ARTICLE	IF	CITATIONS
109	Epidemiologic features of a large hepatitis C cohort evaluated in a major health system in the western United States. <i>Annals of Hepatology</i> , 2019, 18, 360-365.	0.6	6
110	Efficacy and safety of ruzasvir 60Âmg and uprifosbuvir 450Âmg for 12Âweeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4 or 6 infection. <i>Journal of Viral Hepatitis</i> , 2019, 26, 675-684.	1.0	6
111	Dendritic cells in NASH: Friend or foe?. <i>Annals of Hepatology</i> , 2013, 12, 508-509.	0.6	5
112	Reviewing the Risk of Colorectal Cancer in Inflammatory Bowel Disease After Liver Transplantation for Primary Sclerosing Cholangitis. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 269-276.	0.9	5
113	Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6: An integrated analysis of phase 2/3 studies. <i>Liver International</i> , 2020, 40, 2385-2393.	1.9	5
114	Effect of Ljpc-401 (synthetic human hepcidin) on Iron Parameters in Healthy Adults. <i>Blood</i> , 2018, 132, 2336-2336.	0.6	5
115	Financial Compensation For Hepatologists in Different Practice Settings. <i>Hepatology</i> , 2019, 69, 2664-2671.	3.6	4
116	Update on hepatitis C treatment: systematic review of clinical trials. <i>Minerva Gastroenterology</i> , 2017, 63, 62-73.	0.3	2
117	Simplified care-pathway selection for nonspecialist practice. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, Publish Ahead of Print, .	0.8	2
118	Long-term outcomes and trends in liver transplantation for hereditary hemochromatosis in the United States. <i>Liver Transplantation</i> , 2023, 29, 15-25.	1.3	2
119	Reply:. <i>Hepatology</i> , 2008, 47, 1795-1796.	3.6	1
120	Disruption of Iron Regulation after Radiation and Donor Cell Infusion. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1173-1181.	2.0	1
121	Appropriate Clinical Genetic Testing of Hemochromatosis Type 2â€“4, Including Ferroportin Disease. <i>The Application of Clinical Genetics</i> , 2021, Volume 14, 353-361.	1.4	1
122	Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. , 2018, 68, 349.		1
123	Pediatric cholestatic liver disease: Successful transition of care. <i>Cleveland Clinic Journal of Medicine</i> , 2019, 86, 454-464.	0.6	1
124	Rusfertide (PTG-300), a Heparin Mimetic, Maintains Liver Iron Concentration in the Absence of Phlebotomies in Patients with Hereditary Hemochromatosis. <i>Blood</i> , 2021, 138, 943-943.	0.6	1
125	1223Ledipasvir/Sofosbuvir is Safe and Effective as a Single-Tablet-Regimen for Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus, Including those with Compensated Cirrhosis. <i>Open Forum Infectious Diseases</i> , 2014, 1, S42-S42.	0.4	0
126	Sofosbuvir/Velpatasvir Plus GS-9857 (100 Milligrams) for 6, 8, or 12 Weeks in Genotype 1-6 Hepatitis C Virus (HCV)-Infected Patients: An Integrated Analysis of Safety and Efficacy From Two Phase 2 Studies. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0



#	ARTICLE	IF	CITATIONS
127	IDDF2018-ABS-0113â€¦The safety and tolerability of sof/vel/vox for 8 or 12 weeks in >1,000 patients treated in the polaris-1, polaris-2, polaris-3, and polaris-4 studies: an integrated analysis. , 2018, , .		0
128	You are what you wheat: effects of a whole-wheat diet compared with a refined-wheat diet on hepatic steatosis. American Journal of Clinical Nutrition, 2018, 108, 1162-1163.	2.2	0
129	IDDF2019-ABS-0134â€¦Sofosbuvir/velpatasvir is effective and safe in patients with concomitant proton pump inhibitor use in clinical studies. , 2019, , .		0
130	IDDF2019-ABS-0211â€¦Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5 or 6 infection: an integrated analysis of phase 2 and 3 studies. , 2019, , .		0
131	Both Alcoholic and Nonalcoholic Steatohepatitis Is an Emerging Indication for Liver Transplantation in the United States. Digestive Disease Interventions, 2020, 04, 223-234.	0.3	0
132	Role of biliary CEACAM6 as a biomarker for cholangiocarcinoma.. Journal of Clinical Oncology, 2013, 31, 177-177.	0.8	0
133	Third-trimester tenofovir to prevent mother-to-child hepatitis B virus transmission. Indian Journal of Medical Research, 2017, 146, 1.	0.4	0
134	Identification of People Infected With Hepatitis C Virus Who Have Never Been Diagnosed. Gastroenterology and Hepatology, 2019, 15, 669-671.	0.2	0
135	Highlights in Primary Biliary Cholangitis From the EASL 2020 Digital International Liver Congress, the ACG 2020 Virtual Annual Scientific Meeting, and the AASLD 2020 Liver Meeting Digital Experience: Commentary. Gastroenterology and Hepatology, 2021, 17, 13-15.	0.2	0
136	An Examination of the Evidence Behind Biochemical Markers in Primary Biliary Cholangitis. Gastroenterology and Hepatology, 2021, 17, 5-11.	0.2	0